Electro-mediated drug administration of mitomycin C in preventing non-muscle-invasive bladder cancer recurrence and progression after transurethral resection of the bladder tumour in intermediate- and high-risk patients

Carando, Roberto; Soldini, Emiliano; Cotrufo, Simone; Zazzara, Michele; Ludovico, Giuseppe Mario

doi:10.1080/2090598x.2020.1816150

Cited by 4 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The largest reported study to date evaluated 124 EMDA/MMC treatments [11-16]. Thus, this research adds to the current literature by describing patient characteristics, efficacy, and recurrence as well as progression outcomes after EMDA/MMC treatments in the largest study reported to date, as shown in Table 4.…”

Section: Discussionmentioning

confidence: 93%

“…At the end of followup, recurrence-free rates were 75, 71.4, 50, and 25% in TaG3, T1G3, CIS, and TaT1G3 + CIS patients, respectively; progression-free rate was 61%. Carando et al [15,16] reported the data of 65 patients and 112 patients affected by NMIBC that performed a complete TURBT followed by EMDA/MMC. At the end of follow-up, recurrence-free rates were 84 and 75% in 65 and 112 patients, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…Carando et al [15, 16] reported the data of 65 patients and 112 patients affected by NMIBC that performed a complete TURBT followed by EMDA/MMC. At the end of follow-up, recurrence-free rates were 84 and 75% in 65 and 112 patients, respectively.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer

et al. 2021

View full text Add to dashboard Cite

Background: Although TURB of tumor (TURBT) by itself can eradicate a non-muscle-invasive bladder cancer (NMIBC) completely, these tumors commonly recur and can progress to MIBC. It is, therefore, necessary to consider adjuvant therapy in most patients. The primary objective of the present study was to report our experience with EMDA/MMC and BCG, considering efficacy, progression, and recurrence, as adjuvant therapy in NMIBC patients; the secondary objective was to assess the efficacy of EMDA/MMC versus BCG as a comparative treatment. Methods: Between April 2016 and February 2020, a series of 216 patients, with a diagnosis of intermediate- and high-risk NMIBC after TURBT, underwent adjuvant intravesical therapy. In 26 cases with a failure of the treatment, in patients unfit and unwilling for radical cystectomy, a repeated intravesical therapy was performed (2 had a twice repetition). Out of 244 adjuvant therapies, 140 EMDA/MMC and 104 BCG treatments were done. The following data were collected for each patient: baseline demographics and clinical data and perioperative and postoperative data. Overall patients’ adjuvant intravesical therapies were included in a prospectively maintained institutional database, and a retrospective chart review was performed. We collected data on 2 main outcomes, recurrence-free survival (defined as a negative cystoscopy, cytology, and/or histology at the evaluation time point) and progression-free survival (defined as a negative cystoscopy or a nonprogressive tumor recurrence). Results: The NMIBC progression rate was higher in BCG than EMDA/MMC but not statistically significant (respectively, 4.2% vs. 2.5%; p = 0.703). In the overall population, the risk of NMIBC recurrence was higher after BCG than EMDA/MMC (p = 0.025). In the subgroups of 59 paired patients with similar characteristics, no difference was observed between groups in NMIBC progression and recurrence. Conclusions: Our findings suggest that EMDA/MMC and BCG are safe and reproducible approaches as adjuvant treatment in NMIBC. EMDA/MMC permits to achieve a fine oncological management as adjuvant treatment in NMIBC, which is not less than that obtained with BCG.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…EMDA protocols adopted by the various centers show slight variations, with earlier studies using a lower current amplitude of 15 mA over shorter time periods of 20 min, while most subsequent studies utilize a maximum of 20 to 23 mA of pulsed DC applied over a duration of 30 min [ 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 ]. No differences in tolerability and adverse side effects were observed with the higher amplitude and longer durations.…”

Section: Pre-clinical Studies and Clinical Applications Of Emda In On...mentioning

confidence: 99%

Electromotive Enhanced Drug Administration in Oncology: Principles, Evidence, Current and Emerging Applications

Min

Saeed

Coene

et al. 2022

Cancers

View full text Add to dashboard Cite

Local-regional administration of cytotoxic drugs is an important adjunct to systemic chemotherapy amongst cancer patients. It allows for targeted delivery of agents at high concentration to target sites while minimizing systemic side effects. Despite the pharmacokinetic advantages of the local–regional approach, drug transport into tumor nodules remains limited due to the biophysical properties of these tissues. Electromotive enhanced drug administration (EMDA) represents a potential solution to overcome challenges in local drug transport by applying electric currents. Through electrokinetic phenomena of electromigration, electroosmosis and electroporation, electric currents have been shown to improve drug penetration and distribution in a wide variety of clinical applications. Amongst patients with non-muscular invasive bladder cancer (NMIBC) and basal and squamous cell skin cancers, EMDA has been successfully adopted and proven efficacious in several pre-clinical and clinical studies. Its application in ophthalmological and other conditions has also been explored. This review provides an overview of the underlying principles and factors that govern EMDA and discusses its application in cancer patients. We also discuss novel EMDA approaches in pre-clinical studies and explore future opportunities of developments in this field.

show abstract

Device-assisted intravesical chemotherapy versus bacillus Calmette–Guerin for intermediate or high-risk non-muscle invasive bladder cancer: a systematic reviewer and meta-analysis

You,

Li,

Qing

et al. 2023

Int Urol Nephrol

View full text Add to dashboard Cite

Electro-mediated drug administration of mitomycin C in preventing non-muscle-invasive bladder cancer recurrence and progression after transurethral resection of the bladder tumour in intermediate- and high-risk patients

Abstract: (2020): Electro-mediated drug administration of mitomycin C in preventing non-muscle-invasive bladder cancer recurrence and progression after transurethral resection of the bladder tumour in intermediate-and high-risk patients, Arab Journal of Urology,

Cited by 4 publications

References 43 publications

Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer

Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer

Electromotive Enhanced Drug Administration in Oncology: Principles, Evidence, Current and Emerging Applications

Device-assisted intravesical chemotherapy versus bacillus Calmette–Guerin for intermediate or high-risk non-muscle invasive bladder cancer: a systematic reviewer and meta-analysis

Contact Info

Product

Resources

About